Details

Autor(en) / Beteiligte

• Yusuf, Salim
• Diener, Hans-Christoph
• Sacco, Ralph L
• Cotton, Daniel
• Ôunpuu, Stephanie
• Lawton, William A
• Palesch, Yuko
• Martin, Reneé H
• Albers, Gregory W
• Bath, Philip
• Bornstein, Natan
• Chan, Bernard P.L
• Chen, Sien-Tsong
• Cunha, Luis
• Dahlöf, Björn
• De Keyser, Jacques
• Donnan, Geoffrey A
• Estol, Conrado
• Gorelick, Philip
• Gu, Vivian
• Hermansson, Karin
• Hilbrich, Lutz
• Kaste, Markku
• Lu, Chuanzhen
• Machnig, Thomas
• Pais, Prem
• Roberts, Robin
• Skvortsova, Veronika
• Teal, Philip
• Toni, Danilo
• VanderMaelen, Cam
• Voigt, Thor
• Weber, Michael
• Yoon, Byung-Woo

Titel

Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events

Ist Teil von

• The New England journal of medicine, 2008-09, Vol.359 (12), p.1225-1237

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2008

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In a multicenter trial, 20,332 patients who had recently had an ischemic stroke were randomly assigned to receive either telmisartan or placebo. All patients also received medications for blood-pressure control at the investigators' discretion. At a mean follow-up of 2.5 years, there was no significant difference between the two study groups in the rates of recurrent stroke or major cardiovascular events. Patients who had recently had an ischemic stroke were randomly assigned to receive either telmisartan or placebo. At a mean follow-up of 2.5 years, there was no significant difference between the study groups in the rates of recurrent stroke or major cardiovascular events. Stroke is the second most frequent cause of death in the world and is responsible for about 5 million deaths each year. 1 An additional 15 million persons have nonfatal strokes, with about a third having disabling consequences. Elevated blood pressure is the strongest risk factor for stroke, and lowering of blood pressure, especially in patients with substantially elevated levels (e.g., systolic pressure, >160 mm Hg), reduces the risk of stroke. 2 After a stroke, lowering blood pressure with a combination of an angiotensin-converting–enzyme (ACE) inhibitor and a diuretic reduced rates of recurrent stroke in the Perindopril Protection against Recurrent Stroke Study . . .